Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-088514 · Präparat HOS-083663
7 sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis have not been studied and should be avoided. ANTIFUNGALS Fluconazole/Lamivudine Interaction not studied. As only limited data are Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical (400 mg once daily/200 mg significance is not known. thrice daily) (UGT inhibition) Monitor for signs of zidovudine toxicity (see section 4.8). ANTIMYCOBACTERIALS Rifampicin/Lamivudine Interaction not studied. Insufficient data to Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage mg once daily/200 mg thrice adjustment. daily) (UGT induction) ANTICONVULSANTS Phenobarbital/Lamivudine Interaction not studied. Insufficient data to Phenobarbital/Zidovudine Interaction not studied. recommend dosage adjustment. Potential to slightly decrease zidovudine plasma concentrations through UGT induction. Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin Phenytoin/Zidovudine Phenytoin AUC concentrations. Valproic acid/Lamivudine Interaction not studied. As only limited data are Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical (250 mg or 500 mg thrice significance is not known. daily/100 mg thrice daily) (UGT inhibition) Monitor for signs of zidovudine toxicity (see section 4.8). ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS) Ranitidine/Lamivudine Interaction not studied. No dosage adjustment necessary. Clinically significant interaction unlikely. Ranitidine eliminated only in part by renal organic cation transport system. Ranitidine/Zidovudine Interaction not studied Cimetidine/Lamivudine Interaction not studied. No dosage adjustment necessary. Clinically significant interaction unlikely. Cimetidine eliminated only in part by renal organic cation transport system. Cimetidine/Zidovudine Interaction not studied. CYTOTOXICS Cladribine/Lamivudine Interaction not studied Therefore the concomitant use of lamivudine with cladribine In vitro lamivudine inhibits the is not recommended intracellular phosphorylation of (see section 4.4) cladribine leading to a potential risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) fluconazole (HOS-087945) phenobarbital (HOS-085617) phenytoin (HOS-084531) valproic acid (HOS-088515) histamine (HOS-088516) ranitidine (HOS-085660) cimetidine (HOS-085835) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 80bfcdbc676c074809992c973802a382b624f4a50bfeaaede637578173acc0cf · Zeichen 3740–7470 im Abschnitt